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Objective. The aim of this study was to examine the epidemiology, natural history, treatment pattern, and predictors of long-term
survival of signet ring prostate carcinoma (SRPC) patients based on the analysis of the national Surveillance, Epidemiology, and
EndResults(SEER)database.Methods& Results.Between1980and2004,atotalof93patientswithpathologicallyconﬁrmedSRPC
were identiﬁed. The mean age was 70 ± 11 years old. 82.8% of the patients had poorly or undiﬀerentiated histology grade. 13.9%
patients presented with metastatic disease. The 1-, 3-, and 5-year cancer-speciﬁc survival rates were 94.6%, 89.6%, and 83.8%,
respectively. Using multivariate Cox proportional hazard model, younger age (40–50 versus age >70 yrs, P = .01), advanced tumor
stage (distant versus local/regional, P = .02), and earlier diagnosis year (before 1995 versus after 1995, P = .01) were predictors
of worse cancer speciﬁc survival. Conclusions. Despite more aggressive cancer therapy, younger SRPC patients had a worse cancer
speciﬁc survival. This information could be useful when counseling these patients and emphasizes the need for new strategies and
molecular-based therapeutic approaches for younger patients with SRPC.
1.Introduction
Since the ﬁrst description by Giltman in [1], approximately
100 cases of prostate signet ring cell carcinoma (SRCC)
have been reported. One previous report reviewed 200
cases of prostatic adenocarcinoma; the authors identiﬁed
ﬁve cases (2.5%) with signet ring cell diﬀerentiation [2].
Signet ring cells are frequently seen as a minor population
in high grade adenocarcinomas, while the pure form of this
entity is extremely rare [3]. Microscopically, signet ring cells
are characterized by a clear cytoplasmic vacuole eccentric
nucleus.Thesecellsmaybearrangedinsheets,smallclusters,
or as dispersed single cells. The tumor cells are positive for
both prostate-speciﬁc antigen (PSA) and prostate-speciﬁc
acid phosphatase (PAP). A minority of cells may stain weakly
positive for mucin. These characteristics can be used to
diﬀerentiate them from intestinal tumor [4]. Saito and Iwaki
[5] reviewed all the mucin-producing adenocarcinomas of
the prostate reported in the English literature and described
three subtypes: (1) mucinous carcinoma; (2) signet ring
cell carcinoma, deﬁned as having signet ring morphologic
structure in at least 25% of the tumor volume; (3) mucinous
carcinoma with signet ring cells, deﬁned as having extracel-
lular mucin in at least 25% of the tumor volume or having
signet ring morphologic structure in less than 25% of the
tumor volume.
Thus, signet ring prostatic carcinoma (SRPC) is a rare
form of adenocarcinoma. Although several small case series
have been reported, most of these reports were retrospective
reviews from single institutional experiences and focused
on the histopathology [2, 6–10], and there are even fewer
reports concerning treatment outcomes and followup. The
demographic characteristics and clinical sequella of SRPC
remains ill-deﬁned, and patients’ outcomes are inconsistent
among studies [1, 5, 11]. The clinical signiﬁcance and
biologic behavior of this subgroup of primary prostate
carcinomas need to be further characterized by performing
more extensive studies with larger sample size and long-
term followup. The aim of this study is to examine the
demographic and clinical characteristics of patients with2 Prostate Cancer
SRPCidentiﬁedthroughtheSurveillance,Epidemiology,and
End Results (SEER) Program database and to determine the
prognostic factors impacting cancer-speciﬁc survival.
2. Methods
2.1. Data Source. SEER retrieves patient records from mul-
tiple locations across the United States and is regarded as a
model population-based tumor registry. SEER 9, 13, and 17
registriescoverapproximately9.5%,13.8%,and26.2%ofthe
total US population, respectively. In this study, we used the
SEER data based on the November 2006 submission. Data
forthisstudywereobtainedfromSEER∗ Statpublic-usedata
ﬁles, available on internet or CD-ROM from the National
Cancer Institute [12].
2.2. Study Population. The cases of SRPC were extracted
from the SEER on the basis of anatomic site and histology
type. All patients over the age of 18 years diagnosed with
SRPC in the SEER national cancer registry between January
1980 and December 2004 were evaluated. Cases identiﬁed at
the time of autopsy or by death certiﬁcate only and patients
with more than one primary tumor were excluded from the
survival analyses.
2.3. Variables. Patients’ social demographic characteristics
(i.e., age, race/ethnicity, and marital status) and tumor grade
and stage at the time of diagnosis were determined from the
SEER database. SEER general summary stage [12] classiﬁes
patients as having local, regional (extension into adjacent
tissues or nodal involvement), or distant disease. The World
Health Organization’s standard grading system was used
with four separate categories (well, moderately well, poorly
diﬀerentiated, and undiﬀerentiated). For prostate cancer
cases, SEER database recorded the highest value of PSA tests
at the time of diagnosis under the variable named “Tumor
Marker 2”. In the database, PSA was categorized as (a) none,
(b) positive, (c) Negative, (d) borderline, undetermined
whether positive or negative, (e) ordered, but results not in
chart, and (f) unknown or no information [12]. According
to the available information, we grouped PSA levels into
three groups in this study: above normal (positive), normal
(negative), or unknown.
2.4. Statistical Analysis. Age-adjusted incidence rates and
their 95% CIs were calculated for SRPC in all patients, in
men and women separately and in each of the 3 broad race
categories (whites, blacks, and others). For calculation of the
age-adjusted incidence rates, the US general population for
the year 2000 was used as a standard population.
Discrete data are reported as frequencies and compared
by chi-square and Fisher’s exact tests as appropriate. Con-
tinuous data are reported as mean ± SD and compared by
student’s t-test. Multivariate logistic regression analyses were
used to determine the factors associated with receipt of rad-
ical prostatectomy and radiation therapy. Survival duration
was measured by the Kaplan-Meier method and compared
by the log rank test. Multivariable Cox proportional hazards
Table 1: Age-Adjusted Incidence Rate of Signet Ring Prostate
Carcinoma.
Age-adjusted incidence rate∗ 95% CI
All 0.0088 (0.0065–0.0116)
White 0.0077 (0.0054–0.0107)
Black 0.00187 (0.0085–0.0353)
Others 0.0081 (0.002–0.0206)
∗Rates are per 100,000 populations(95% conﬁdence interval)age-adjusted
to year 2000 US standard population.
model was used to identify independent predictors of long-
term cancer-speciﬁc death.
SEER∗Stat 6.2.4 (Surveillance Research Program, Na-
tional Cancer Institute) was used for incidence and limited-
durationprevalenceanalyses.Allotherstatisticalcalculations
were performed by SPSS 12.0 (Apache Software Foundation
2000). Comparative diﬀerences were considered statistically
signiﬁcant when the P-value was <.05.
3. Results
3.1.FrequencyandIncidence. Atotalof588,101patientswith
prostate cancer were identiﬁed in the SEER 17 registries
between January 1980 and December 2004. When we
restricted the search to signet ring cell carcinoma histology, a
total of 93 patients were identiﬁed, representing 0.02% of all
patients with prostate cancers.
Using linked population ﬁles, the incidence of SRPC
as a rate per 100,000 per year, age-adjusted to year 2000
US standard population was calculated. An age-adjusted
incidence of 0.0088 per 100,000 was observed in the study
periods. Detailed incidence data by time period, gender, and
race are included in Table 1.
3.2. Patient and Tumor Characteristics. Table 2 provides a
detailed demographic, tumor characteristics, and treatment
information on 93 patients with SRPC. Of the 93 patients
with SRPC identiﬁed in the SEER database during the study
period, the mean age of the cohort was 70 ± 11 years old
(median age, 69 years, with a range of 40 to 92 years). The
majority of patients were white and accounts for 68 patients
(73.1%). There were 14 African-American patients (15.1%),
and the other ethnic groups comprised 11 patients (11.8%).
Ofthe93patients,82.8%patientshadhighgrade(poorly
orundiﬀerentiated)histology;13.9%patientspresentedwith
distant stage. Among the patients with known PSA value
(n = 35), 80% of patients were found with elevated PSA,
while the remaining 20% had a normal PSA value.
Overall, the median duration of followup was 30 (range
0–238) months, and the median duration of follow-up for
censored patients was 2.7 years. Finally, a total 39 of 93
(41.9%) patients died during the followup period.
3.3. Predictor of Receipt of Prostatectomy and Radiation Ther-
apy. Cancer-directed surgery was performed in 40 (45%)
patients; among them, 25 patients (26.9%) had radical
prostatectomy. A total of 25 (26.9%) of the patients receivedProstate Cancer 3
Table 2: Characteristics of 93 Patients with Signet Ring Prostate
Carcinoma (Diagnosed Between January 1980 and December
2004).
Characteristics Total patients n (%)
Age groups, n (%)
40–50yrs 5 (5.4)
51–60yrs 13 (14.0)
61–70yrs 30 (32.2)
>70yrs 45 (48.4)
Race
Black 14 (15.1)
White 68 (73.1)
Others 11 (11.8)
Married
Yes 64 (68.8)
No 18 (19.4)
Unknown 11 (11.8)
Grade
Moderately-diﬀerentiated 9 (9.7)
Poorly-diﬀerentiated 74 (79.6)
Undiﬀerentiated 3 (3.2)
Unknown 7 (7.5)
PSA
Above normal 29 (31.2)
Normal 6 (6.5)
Unknown 58 (62.4)
Stage
Local/regional 72 (77.9)
Distant 13 (13.9)
Unknown 8 (8.6)
Year of diagnosis
1980–1994 22 (23.7)
1995–2004 71 (76.3)
Prostatectomy
Yes 25 (26.9)
No 68 (73.1)
Radiation
Yes 25 (26.9)
No 66 (71.0)
Unknown 2 (2.1)
PSA: prostate speciﬁc antigen.
primaryradiationtherapy,withadjuvantradiationfollowing
surgery in 5(5.4%) patients.
In a logistic regression analysis, age, marital status, and
tumor stage signiﬁcantly correlated with radical prostate-
ctomy; the patients who were older, unmarried and had
advanced stage tumor were less likely to elect radical
prostatectomy. In a separate analysis restricted to patients
with local/regional disease, younger age and being married
remained independent predictors of radical prostatectomy
(Table 3).
Logistic regression analyses of factors associated with
radiation therapy were also performed. African Americans
were more likely to receive radiation therapy compared to
the other races. Prostatectomy receipts were found to be less
likely to receive radiation therapy (Table 4).
3.4. Long-Term Cancer-Speciﬁc Survival. For cancer-speciﬁc
survival analyses, the cases that were diagnosed at autopsy
or on the basis of death certiﬁcates only as well as patients
with multiple primaries were excluded. A total 81 patients
were included in the survival analysis. Table 5 presents the
cancer-speciﬁc survival rates according to patient and tumor
characteristics. Overall cancer-speciﬁc survival rates at 1-,
3-, and 5-year were 94.6%, 89.6%, and 83.8%, respectively
(Figure 1(a)). The 1-, 3-, and 5-year cancer-speciﬁc survival
ratesforpatientswithlocal/regionalstagetumorwere96.4%,
91.9%, and 88.3% and for patients with distant stage tumor
were 90.0%, 78.8%, and 39.4%, respectively (Figure 1(b)).
The median cancer-speciﬁc survival for patients who under-
went prostatectomy was 100 months (95% CI 96–104).
The 1-, 3-, and 5-year cancer-speciﬁc survival rates for
patients who underwent prostatectomy were 94.7%, 89.2%,
and 89.2%, respectively. There was a signiﬁcant diﬀerence in
survival between diﬀerent age subgroups. The 1-, 3-, and 5-
year cancer-speciﬁc survival rates for patients age >70 years
old group were 94.7%, 94.7%, and 88% for patients ages
between 40–50 years old were 80%, 60%, and 60%, respec-
tively (Figure 1(c)). The 1-, 3-, and 5-year cancer-speciﬁc
survival rates were signiﬁcantly improved for patients who
werediagnosedinlateryears(1995–2004)comparedtothose
in earlier years (1980–1994) (Figure 1(d)).
Table 6 presents the result of multivariate survival anal-
yses using Cox proportional hazard model. After adjusting
for the demographic, clinical, and treatment-related factors,
younger age was identiﬁed as an independent predictor of
poor survival in comparison to other older age subgroups
(51–60yrs versus 40–50yrs, HR = 0.09; 61–70yrs versus
40–50yrs, HR = 0.04; >70yrs versus 40–50yrs, HR =
0.02). The tumor stage at diagnosis was another signiﬁcant
predictor of cancer-speciﬁc survival. Compared to patients
with local/regional disease, patients with distant disease had
nearly 11-fold increased risk of cancer-speciﬁc death from
SRPC (P = .02). The other signiﬁcant factor associated
with survival was year of diagnosis (P = .01). Patients
with SRPC diagnosed after1995 had signiﬁcantly decreased
cancer-speciﬁc death rate compared to those diagnosed
before 1995 (HR = 0.12).
4. Discussion
Because of the rarity of SRPC, previously published infor-
mation has been based on case series and single institu-
tional experiences, which may not represent “real world”
patients. Large, tertiary-care referral centers with mature
local, regional, and national referral patterns may have a
disproportionate number of advanced and recurrent tumors
as well as a healthier population able to travel to these
centers. This study takes advantage of the vast amount of4 Prostate Cancer
Table 3: Multivariate Analyses of Factors Associated with Receipt of Radical Prostatectomy in Patients with Localized/Regional Stage Signet
Ring Prostate Carcinoma.
Characteristics Group OR 95% CI P-value
Age Continuous 0.80 0.71–0.90 <.001
Ethnicity White 1.00
Black 3.85 0.39–38.0 0.25
Others 1.79 0.22–14.4 0.58
Marital status Married 1.00
No 0.12 0.02–0.85 0.03
Year of Diagnosis 1980–1994 1.00
1995–2004 0.62 0.13–2.97 0.55
Radiation No 1.00
Yes 0.10 0.01–0.92 0.04
OR: odds ratio; CI: conﬁdence interval.
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Figure 1: Kaplan-Meier survival curves for (a) cancer-speciﬁc survival of entire cohort, (b) cancer-speciﬁc survival by subgroups of diﬀerent
tumor stages, (c) cancer-speciﬁc survival by age subgroups, and (d) cancer-speciﬁc survival rate of patients by subgroups of diﬀerent
diagnosis year. P-value shown for log-rank test between two groups.Prostate Cancer 5
Table 4: Multivariate Analyses of Factors Associated with Receipt of Radiation in Patients with Signet Ring Prostate Carcinoma.
Characteristics Group OR 95% CI P-value
Age Continuous 0.97 0.92–1.03 0.34
Ethnicity White 1.00
Black 8.67 1.66–45.36 0.01
Others 0.44 0.04–4.54 0.49
Year of Diagnosis 1980–1994 1.00
1995–2004 1.27 0.35–4.67 0.72
SEER stage Local/regional 1.00
Distant 0.30 0.06–1.51 0.15
Unstaged 0.31 0.03–3.0 0.31
Marital status Married 1.00
No 0.47 0.14–1.62 0.23
Prostatectomy No 1.00
Yes 0.06 0.01–0.44 0.006
OR: odds ratio; CI: conﬁdence interval.
Table 5: 1-, 3-, and 5-year cancer-speciﬁc Survival of Patients with Signet Ring Prostate Carcinoma According to Demographic and Clinical
Characteristics.
Characteristics Cancer-Speciﬁc Survival Rate (%)
1-year 3-year 5-year
Overall patients 94.6 89.6 83.8
Age subgroups 40–50yrs 80 60 60
51–60yrs 88.8 77.8 77.8
61–70yrs 94.4 94.4 85.9
>70yrs 94.7 94.7 88
SEER stage Local/regional 96.4 91.9 88.3
Distant 90.0 78.8 39.4
unstaged 87.5 87.5 87.5
Prostatectomy No 94.5 80.9 80.9
Yes 94.7 89.2 89.2
Year 1980–1994 88.9 76.6 68.9
1995–2004 96.5 94.3 89.8
data collected by the national SEER Program to examine
the largest series of SRPC reported to date. We examine
the incidence, natural history, predictors of utilization of
prostatectomy, radiation therapy, and factors that aﬀect the
survival for SRPC by using the national population-based
database. In this study, the total SRPC cases accounted for
approximately 0.02% of primary prostate tumors included
in the SEER database during study period. This incidence
calculated in the SEER database is lower than reported
in single institution studies [2, 5]. One of the potential
explanations for these ﬁndings is referral bias. The patients
with rare histology subtype are more likely to visit referral
centers for a second opinion; compared with a community
counterpart, pathologists from tertiary hospital and referral
centers are more likely to have expertise in indentifying this
rare subtype of histology.
The optimal treatment strategy for this subtype of
prostate cancer is unknown since there is no clinical trial
speciﬁcally designed for SRPC. In this study, we indentiﬁed
signiﬁcant age-and racial-related disparities as an important
factor for selecting prostatectomy or radiation therapy,
which is consistent with previous ﬁndings [11, 13, 14].
For example, younger age was the strongest predictor for
receiving radical prostatectomy rather than external beam
radiotherapy (EBRT) and younger age as a predictor of
aggressive local therapy, while older prostate cancer patients
were often treated less aggressively [15, 16]. Eﬀorts should
be made to indentify high risk individuals for potential
intervention in order to reduce these disparities.
Consistent with single institution studies, the cancer-
speciﬁc survival of SRPC is poor. In our study, the 3- and 5-
year survival rates of SRPC were 89.6% and 83.8% (Table 5),
which are signiﬁcantly lower, in comparison with 5- and 10-
yearsurvivalratesof99.9%and92%,respectively,inpatients
with prostate cancer as a whole [17].
Despite receiving more aggressive therapy, younger
patients in this study had a poorer prognosis (Figure 1(c)).
Controversyexistsregardingtheimportanceofpatientagein
disease behavior of prostate cancer. In several series, younger
age at diagnosis has been correlated with more aggressive6 Prostate Cancer
Table 6: Multivariate Analyses of Factors Associated with Cancer-Speciﬁc Mortality in Patients with Signet Ring Prostate Carcinoma.
Characteristics Group HR 95% CI P-value
Age 40–50yrs 1.00
51–60yrs 0.09 0.007–1.15 0.06
61–70yrs 0.04 0.003–0.58 0.02
>70yrs 0.02 0.001–0.37 0.01
Ethnicity White 1.00
Black 2.32 0.23–23.5 0.47
Others 2.51 0.29–21.6 0.40
SEER Stage Local/regional 1.00
Distant 10.9 1.44–82.09 0.02
Unstaged 5.23 0.70–39.3 0.11
Marital status Married 1.00
No 0.11 0.01–0.93 0.04
Diagnosis year 1980–1994 1.00
1995–2004 0.12 0.02–0.62 0.01
Prostatectomy No 1.00
Yes 0.57 0.07–4.40 0.59
Radiation No 1.00
Yes 0.28 0.03–2.52 0.25
HR: Hazard ratio; CI: Conﬁdence interval.
tumor types and subsequent mortality [18, 19]. Conversely,
other studies have shown survival rates among younger
patients to be equivalent or even superior to those of elderly
patients [20–22]. Lin et al. [22] examined the association
between age at diagnosis and grade, stage, treatment, and
survival outcomes in men who were diagnosed during the
era of PSA testing. Younger men were more likely to undergo
prostatectomy, have lower grade cancer, and, as a group, to
have better overall and equivalent cancer-speciﬁc survival at
10 years compared with older men. However, among men
with high grade and locally advanced prostate cancer, the
younger men had a poorer prognosis compared to older
men. The subgroup of men with high grade and locally
advanced prostate cancer described in Lin’s study are very
similar to our subjects. 82.8% of our entire study cohort
(90% of the patients with known histology grade) had
e i t h e rp o o r l yo ru n d i ﬀerentiated histology. The ﬁndings
collectively, from this study and others, support the view that
prostate cancer is a heterogeneous disease, diﬀerent subtypes
may represent diﬀerent diseases [22–25]. In practical terms,
these ﬁndings suggest that better diagnosis and therapy of
prostate cancer are likely to be achieved by investigating
each subtype of prostate cancer separately rather than
grouping them all together [25]. Our ﬁnding of subtype-
related diﬀerences in survival has signiﬁcant therapeutic
implications with regard to patient selection, trial design,
and therapy recommendations and warrants further study to
oﬀer this poor-prognosis group of men better preventative
and therapeutic options.
Cancer incidence is known to be increased with age
[12, 17]. Paradoxically, tumor growth and metastasis often
occurred at a slower rate in aged human and animal popula-
tions. For example, tumors grow slower and metastasize less
in old patients with cancer [26–28]. In experimental models,
tumor growth has frequently been shown to be slower and
to display a reduced aggressiveness in aged as compared
to young animals [29]. The mechanisms responsible for
thesephenomenonshavenotyetbeenestablished.Decreased
proliferative capacity [30], decline in growth factors with age
[31], and age-related changes in antitumor immunity [32]
have been suggested. Recently, an increased apoptotic cell
deathhasalsobeenlinkedtothereducedmalignantbehavior
of tumors in the aged [33].
Currently, there is no literature addressing the impact
of age on survival, speciﬁcally on SRPC. Our ﬁnding of
age as an independent prognostic factor for this disease
is interesting. The survival diﬀerence among diﬀerent age
groups might be explained by a diﬀerence in the biologic
behavior of SRPC in the younger patients and elderly.
Molecular research may provide additional insights into
these questions. Similarly, breast cancer arising in young
women is correlated with inferior survival and higher
incidence of negative clinicopathologic features. A large-
scale genomic analysis illustrates that breast cancer arising
in young women is a unique biologic entity driven by
unifying oncogenic signaling pathways [34]. Age-speciﬁc
diﬀerences in oncogenic pathway dysregulation have also
been investigated in patients with acute myeloid leukemia
[35]. The age-related diﬀerential biological behavior of
tumors also implies the necessity of a diﬀerential therapy
f o rc a n c e rp a t i e n t so fd i ﬀerent ages. In fact older patients
are now more frequently treated with radiation therapy
than surgery modulated by projected patient longevity and
biomarkers predicting cancer recurrence 7 years following
initial biopsy or resected tumor specimen using Systems
Pathology [35, 36].Prostate Cancer 7
Similar to the ﬁndings of increasing in 5-year survival in
men with prostate cancer in post-PSA era, we also observed
a signiﬁcant improvement in the outcome of patients with
SRPC during this period (Figure 1(d)). These improvements
were consistent in all SEER stage groups and are likely due to
widelyapplicationofPSAscreening,earlydiagnosis,advance
in local and systemic therapy, and increasing adoption of
multidisciplinary prostate cancer care [14, 17].
Our ﬁndings should be interpreted with caution. First,
this is a nonrandomized study; therefore, selection bias
might have been present because patients undergoing
surgery tend to be healthier. Although we adjusted for
diﬀerences in demographic and tumor factors, residual
confounding might still exist. Second, the pathological
diagnoses in SEER were based on local pathologists’ reports,
and there was no central review of pathology reports. In
addition, SEER data did not allow us to examine receipt
of hormone or chemotherapy and patients’ comorbidities.
However, the analysis reported here attempted to overcome
this data limitation by measuring prostate cancer-speciﬁc
survival, rather than overall survival. Finally, the sample size
in our study may still not be large enough to fully describe
the factors that aﬀect the incidence, treatment choice, and
survival of this rare prostate cancer subtype. Our ﬁndings
may not necessarily be generalized to patients with prostate
adenocarcinoma as a whole.
Strengths of this study include the population-based
design, larger sample size, and inclusion of a broad spectrum
of hospitals in the analysis. Having a larger sample size is of
particular importance for analysis of rare subtype prostate
cancersuchasSRPC,whereitisnearlyimpossibleforasingle
institution to collect enough cases to facilitate a meaningful
analysis regarding prognostic factors.
5. Conclusions
Based on the analysis of a population-based database,
we report the results of the largest series of SRPC in
the literature. Patients with SRPC have a worse survival
compared to patients with other types of prostate cancer.
Younger SRPC patients have signiﬁcantly lower cancer-
speciﬁc survival rate compared to their older counterparts.
Further study to elucidate the mechanism of the diﬀerential
biological behavior of SRPC in relation to host age is
planned. The development of new strategies and molecular-
based therapeutic approaches for younger patients with this
aggressive tumor is urgently needed.
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